retatrutide clinical trial duration Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP Lilly's triple agonist, retatrutide, delivered

As incretinas, como o GLP-1 e o GIP (glucose-dependent insulinotropic polypeptide), promovem a secreo de insulina e inibem a liberao de glucagon, resultando em uma reduo dos nveis de glicose no sangue aps as refeies (LISSI

Most patients start with weekly injections, though some may move to longer intervals depending on their response

Add a Scalp Serum to Your Routine The scalp is the foundation of healthy hair

2019;317:H711H725

SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists

Why is it important to customize GLP-1 dosing